Lake Street Advisors Group LLC Purchases 218 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lake Street Advisors Group LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 41.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 746 shares of the biopharmaceutical company’s stock after purchasing an additional 218 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Regeneron Pharmaceuticals were worth $718,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Arjuna Capital boosted its stake in Regeneron Pharmaceuticals by 6.9% in the 1st quarter. Arjuna Capital now owns 279 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 18 shares during the period. Bessemer Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 107.1% during the 1st quarter. Bessemer Group Inc. now owns 5,075 shares of the biopharmaceutical company’s stock worth $4,886,000 after buying an additional 2,624 shares in the last quarter. Capitolis Liquid Global Markets LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $36,575,000. UniSuper Management Pty Ltd raised its holdings in shares of Regeneron Pharmaceuticals by 174.1% during the 1st quarter. UniSuper Management Pty Ltd now owns 2,409 shares of the biopharmaceutical company’s stock worth $2,319,000 after buying an additional 1,530 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 17.5% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 6,920 shares of the biopharmaceutical company’s stock worth $6,660,000 after buying an additional 1,030 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 2.5 %

Shares of Regeneron Pharmaceuticals stock traded up $26.44 on Thursday, hitting $1,087.30. 160,037 shares of the company’s stock traded hands, compared to its average volume of 465,921. Regeneron Pharmaceuticals, Inc. has a one year low of $723.56 and a one year high of $1,106.16. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company has a fifty day moving average of $1,030.00 and a two-hundred day moving average of $974.95. The company has a market capitalization of $119.81 billion, a price-to-earnings ratio of 31.34, a price-to-earnings-growth ratio of 2.19 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.02 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Bank of America boosted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price for the company. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,074.95.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,074 shares of company stock worth $64,546,123. Corporate insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.